Insulet Co. (NASDAQ:PODD) Director John A. Fallon Sells 9,000 Shares

Insulet Co. (NASDAQ:PODD) Director John A. Fallon sold 9,000 shares of the stock in a transaction that occurred on Wednesday, March 14th. The stock was sold at an average price of $84.10, for a total transaction of $756,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

NASDAQ:PODD opened at $83.77 on Friday. Insulet Co. has a 1 year low of $38.43 and a 1 year high of $88.88. The company has a current ratio of 6.24, a quick ratio of 5.85 and a debt-to-equity ratio of 3.57. The firm has a market capitalization of $4,891.41, a P/E ratio of -182.11 and a beta of 1.38.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). Insulet had a negative net margin of 5.79% and a negative return on equity of 29.73%. The firm had revenue of $130.50 million during the quarter, compared to analyst estimates of $125.16 million. During the same quarter in the previous year, the business posted ($0.16) earnings per share. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. research analysts forecast that Insulet Co. will post -0.29 EPS for the current year.

A number of large investors have recently bought and sold shares of the stock. Frontier Capital Management Co. LLC grew its stake in Insulet by 42.4% in the 4th quarter. Frontier Capital Management Co. LLC now owns 2,096,131 shares of the medical instruments supplier’s stock valued at $144,633,000 after buying an additional 624,465 shares during the last quarter. Fred Alger Management Inc. grew its stake in Insulet by 32.5% in the 4th quarter. Fred Alger Management Inc. now owns 1,808,616 shares of the medical instruments supplier’s stock valued at $124,795,000 after buying an additional 443,970 shares during the last quarter. Millennium Management LLC grew its stake in Insulet by 154.1% in the 4th quarter. Millennium Management LLC now owns 941,567 shares of the medical instruments supplier’s stock valued at $64,968,000 after buying an additional 571,082 shares during the last quarter. Renaissance Technologies LLC grew its stake in Insulet by 328.2% in the 4th quarter. Renaissance Technologies LLC now owns 661,200 shares of the medical instruments supplier’s stock valued at $45,623,000 after buying an additional 506,800 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Insulet by 104.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 611,595 shares of the medical instruments supplier’s stock valued at $34,035,000 after buying an additional 313,093 shares during the last quarter.

PODD has been the subject of a number of research analyst reports. Barclays reiterated a “buy” rating and issued a $78.00 target price on shares of Insulet in a research report on Wednesday, December 13th. UBS upgraded shares of Insulet from a “market perform” rating to an “outperform” rating in a research report on Monday, January 8th. Raymond James Financial upgraded shares of Insulet from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a research report on Monday, January 8th. Zacks Investment Research lowered shares of Insulet from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Finally, BidaskClub upgraded shares of Insulet from a “sell” rating to a “hold” rating in a research note on Friday, January 26th. Seven equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Insulet currently has an average rating of “Buy” and a consensus target price of $75.00.

TRADEMARK VIOLATION WARNING: “Insulet Co. (NASDAQ:PODD) Director John A. Fallon Sells 9,000 Shares” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/08/john-a-fallon-sells-9000-shares-of-insulet-co-podd-stock.html.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Insider Buying and Selling by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply